Characterization of binge-dosed methamphetamine-induced neurotoxicity and neuroinflammation

NeuroToxicology

Volumn 50, Issue , 2015, Pages 131-141

  McConnell, Sarah E A ^a,b   O'Banion, M Kerry ^a   Cory Slechta, Deborah A ^a   Olschowka, John A ^a   Opanashuk, Lisa A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b NONE   (United States)

Author keywords

Astrocytes; Methamphetamine; Microglia; Neuroinflammation; Neurotoxicity; Striatum

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; TYROSINE 3 MONOOXYGENASE; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; BIOGENIC AMINE; CALCIUM BINDING PROTEIN; CENTRAL STIMULANT AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTHERMIA; HYPOACTIVITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BODY TEMPERATURE; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ELECTROCHEMICAL ANALYSIS; ENCEPHALITIS; METABOLISM; MOTOR ACTIVITY; MOUSE; NEUROTOXICITY SYNDROMES; PATHOPHYSIOLOGY; TIME FACTOR;

ANIMALS; BIOGENIC MONOAMINES; BODY TEMPERATURE; CALCIUM-BINDING PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCHEMICAL TECHNIQUES; ENCEPHALITIS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MOTOR ACTIVITY; NEUROTOXICITY SYNDROMES; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84940654619     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2015.08.006     Document Type: Article

References (45)

1. Asanuma M., Miyazaki I., Higashi Y., Tsuji T., Ogawa N. Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Ann. N. Y. Acad. Sci. 2004, 1025:69-75.
2. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exp. Ther. 1994, 268:1571-1580.
3. Chen H., Wu J., Zhang J., Fujita Y., Ishima T., Iyo M., Hashimoto K. Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology (Berl.) 2012, 222:37-45.
4. Clark K.H., Wiley C.A., Bradberry C.W. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox. Res. 2013, 23:174-188.
5. Czeh M., Gressens P., Kaindl A.M. The yin and yang of microglia. Dev. Neurosci. 2011, 33:199-209.
6. Czlonkowska A., Kurkowska-Jastrzebska I. Inflammation and gliosis in neurological diseases - clinical implications. J. Neuroimmunol. 2011, 231:78-85.
7. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008, 27:253-262.
8. De Vito M.J., Wagner G.C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 1989, 28:1145-1150.
9. Deng X., Ladenheim B., Tsao L.I., Cadet J.L. Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J. Neurosci. 1999, 19:10107-10115.
10. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 1995, 38:95-137.
11. Goldman-Rakic P.S., Brown R.M. Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Brain Res. 1982, 256:339-349.
12. Goncalves J., Baptista S., Martins T., Milhazes N., Borges F., Ribeiro C.F., Malva J.O., Silva A.P. Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur. J. Neurosci. 2010, 31:315-326.
13. Grace C.E., Schaefer T.L., Herring N.R., Graham D.L., Skelton M.R., Gudelsky G.A., Williams M.T., Vorhees C.V. Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice. Neurotoxicol. Teratol. 2010, 32:346-355.
14. Harvey D.C., Lacan G., Tanious S.P., Melega W.P. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res. 2000, 871:259-270.
15. Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Iyo M. Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. Biol. Psychiatry 2007, 61:577-581.
16. Itoh T., Murai S., Yoshida H., Masuda Y., Saito H., Chen C.H. Effects of methamphetamine and morphine on the vertical and horizontal motor activities in mice. Pharmacol. Biochem. Behav. 1987, 27:193-197.
17. Jung B.D., Shin E.J., Nguyen X.K., Jin C.H., Bach J.H., Park S.J., Nah S.Y., Wie M.B., Bing G., Kim H.C. Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem. Int. 2010, 56:229-244.
18. Kawasaki T., Ishihara K., Ago Y., Nakamura S., Itoh S., Baba A., Matsuda T. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur. J. Pharmacol. 2006, 542:92-99.
19. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
20. Kuhn D.M., Francescutti-Verbeem D.M., Thomas D.M. Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N. Y. Acad. Sci. 2006, 1074:31-41.
21. Lau J.W., Senok S., Stadlin A. Methamphetamine-induced oxidative stress in cultured mouse astrocytes. Ann. N. Y. Acad. Sci. 2000, 914:146-156.
22. LaVoie M.J., Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 1999, 19:1484-1491.
23. LaVoie M.J., Card J.P., Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 2004, 187:47-57.
24. Levi M.S., Divine B., Hanig J.P., Doerge D.R., Vanlandingham M.M., George N.I., Twaddle N.C., Bowyer J.F. A comparison of methylphenidate-, amphetamine-, and methamphetamine-induced hyperthermia and neurotoxicity in male Sprague-Dawley rats during the waking (lights off) cycle. Neurotoxicol. Teratol. 2012, 34:253-262.
25. Maker H.S., Weiss C., Silides D.J., Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 1981, 36:589-593.
26. Miller D.B., O'Callaghan J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 1994, 270:752-760.
27. Miyazaki I., Asanuma M. Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem. Res. 2009, 34:698-706.
28. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 1994, 270:741-751.
29. Robinson T.E., Berridge K.C. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. B 2008, 363:3137-3146.
30. Schep L.J., Slaughter R.J., Beasley D.M. The clinical toxicology of metamfetamine. Clin. Toxicol. (Phila.) 2010, 48:675-694.
31. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., Iwata Y., Tsuchiya K.J., Suda S., Suzuki K., Kawai M., Takebayashi K., Yamamoto S., Matsuzaki H., Ueki T., Mori N., Gold M.S., Cadet J.L. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 2008, 28:5756-5761.
32. Sheng P., Cerruti C., Cadet J.L. Methamphetamine (METH) causes reactive gliosis in vitro: attenuation by the ADP-ribosylation (ADPR) inhibitor, benzamide. Life Sci. 1994, 55:PL51-PL54.
33. Simon S.L., Domier C., Carnell J., Brethen P., Rawson R., Ling W. Cognitive impairment in individuals currently using methamphetamine. Am. J. Addict. 2000, 9:222-231.
34. Singh S., Swarnkar S., Goswami P., Nath C. Astrocytes and microglia: responses to neuropathological conditions. Int. J. Neurosci. 2011, 121:589-597.
35. Sriram K., Miller D.B., O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 2006, 96:706-718.
36. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 2004, 367:349-354.
37. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 2004, 311:1-7.
38. Thomas D.M., Kuhn D.M. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res. 2005, 1050:190-198.
39. UNODC, World Drug Report, 2010 (United Nations Publication, Sales No. E.10.XI.13).
40. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 2001, 158:377-382.
41. Wagner G.C., Ricaurte G.A., Seiden L.S., Schuster C.R., Miller R.J., Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 1980, 181:151-160.
42. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
43. Yu L., Liao P.C. Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J. Neural Transm. 2000, 107:419-427.
44. Yue X., Qiao D., Wang A., Tan X., Li Y., Liu C., Wang H. CD200 attenuates methamphetamine-induced microglial activation and dopamine depletion. J. Huazhong Univ. Sci. Technol. Med. Sci. 2012, 32:415-421.
45. Zhang L., Kitaichi K., Fujimoto Y., Nakayama H., Shimizu E., Iyo M., Hashimoto K. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1381-1393.